[1]
Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15(18): 2721-31.
[2]
Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 2014; 22(2): 79-94. [http://dx.doi.org/10.1007/s10787-013-0191-7]. [PMID: 24178954].
[3]
Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis 2015; 6(1): 15-28.
[4]
Li S, Li Q, Li Y, Li L, Tian H, Sun X. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2015; 10(3)e0119479
[5]
Cruccu G, Di Stefano G, Fattapposta F, et al. L-acetyl-carnitine in patients with carpal tunnel syndrome: Effects on nerve protection, hand function and pain. CNS Drugs 2017; 31(12): 1103-11.
[6]
Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: A pooled data meta-analysis. Pain Physician 2016; 19(2): 11-24.
[7]
Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: A meta-analysis. Pain Physician 2017; 20(5): 353-62.
[8]
Hoy D, March L, Brooks P, et al. The global burden of low back pain: Estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014; 73(6): 968-74.
[9]
Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: Evidence, challenges, and promising directions. Lancet 2018; 391(10137): 2368-83.
[10]
van Tulder M, Koes B, Bombardier C. Low back pain. Best Pract Res Clin Rheumatol 2002; 16(5): 761-75.
[11]
Mathieson S, Kasch R, Maher CG, et al. Combination drug therapy for the management of low back pain and sciatica: Systematic Review and meta-analysis. J Pain 2019; 20(1): 1-15.
[12]
Schreijenberg M, Koes BW, Lin CC. Guideline recommendations on the pharmacological management of non-specific low back pain in primary care - is there a need to change? Expert Rev Clin Pharmacol 2019; 12(2): 145-57.
[13]
Guida G, de Martino M, de Fabiani A, et al. Palmitoylethanolamide (Normast) in chronic neuropathic pain caused by compressive-type lumbar sciatica: A multicenter clinical trial. DOLOR 2010; 25: 35-42.
[14]
Baron R, Binder A. How neuropathic is sciatica? The mixed pain concept. Orthopade 2004; 33(5): 568-75.
[15]
Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009; 13(3): 185-90.
[16]
Roland M, Fairbank J. The roland-morris disability questionnaire and the oswestry disability questionnaire. Spine 2000; 25(24): 3115-24.
[17]
Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P. The number needed to treat: A clinically useful nomogram in its proper context. BMJ 1996; 312(7028): 426-9.
[18]
Freynhagen R, Arevalo Parada H, Calderon-Ospina CA, et al. Current understanding of the mixed pain concept: A brief narrative review. Curr Med Res Opin 2018; 1-16.
[19]
Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 2017; 174(11): 1349-65.
[20]
Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today 2014; 19(10): 1632-9.
[21]
Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: An efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets 2017; 16(6): 705-13.
[22]
Zhao H, Alam A, Chen Q, et al. The role of microglia in the pathobiology of neuropathic pain development: What do we know? Br J Anaesth 2017; 118(4): 504-16.
[23]
Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: Beyond the neuron. Front Cell Neurosci 2018; 12: 72.
[24]
Skaper SD. Mast cell - glia dialogue in chronic pain and neuropathic pain: Blood-brain barrier implications. CNS Neurol Disord Drug Targets 2016; 15(9): 1072-8.
[25]
Luongo L, Guida F, Boccella S, et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Targets 2013; 12(1): 45-54.
[26]
Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: Efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12(1): 34-44.
[27]
Evangelista M, Cilli V, De Vitis R, Militerno A, Fanfani F. Ultramicronized palmitoylethanolamide effects on sleep-wake rhythm and neuropathic pain phenotypes in patients with carpal tunnel syndrome: An open-label, randomized controlled study. CNS Neurol Disord Drug Targets 2018; 17(4): 291-8.
[28]
Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011; 152(1): 14-27.
[29]
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015; 14(2): 162-73.
[30]
Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: A 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11(12): 1282-90.
[31]
Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the american college of physicians. Ann Intern Med 2017; 166(7): 514-30.
[32]
Juanola Roura X, Collantes Estévez E, León Vázquez F, et al. Reccomendations for the detection, study and referral of inflammatory low-back pain in primary care. Reumatol Clin 2015; 11(2): 90-8.
[33]
Fischer BD. GABA<sub>A</sub> Receptors as targets for the management of pain-related disorders: Historical perspective and update. CNS Neurol Disord Drug Targets 2017; 16(6): 658-63.
[34]
Islam N, Abbas M, Rahman S. Neuropathic pain and lung delivery of nanoparticulate drugs: An emerging novel therapeutic strategy. CNS Neurol Disord Drug Targets 2017; 16(3): 303-10.
[35]
Nestmann ER. Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential. Food Sci Nutr 2016; 5(2): 292-309.
[36]
Higgins JPT, Green S, Eds. Cochrane handbook for systematic reviews of interventions version 510 The Cochrane Collaboration 2011. Updated March . 2011.
[37]
Henschke N, Maher CG, Refshauge KM, et al. Characteristics of patients with acute low back pain presenting to primary care in Australia. Clin J Pain 2009; 25(1): 5-11.
[38]
Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine 1993; 18(11): 1433-8.
[39]
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008; 139(3): 541-50.
[40]
Di Cesare Mannelli L, D’Agostino G, Pacini A, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: Pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013; 2013328797
[41]
Seol TK, Lee W, Park S, et al. Effect of palmitoylethanolamide on inflammatory and neuropathic pain in rats. Korean J Anesthesiol 2017; 70(5): 561-6.
[42]
Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P. Misdiagnosed chronic pelvic pain: Pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med 2010; 11(5): 781-4.
[43]
Truini A, Biasiotta A, Di Stefano G, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets 2011; 10(8): 916-20.
[44]
Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014; 2014849623
[45]
Domínguez CM, Martín AD, Ferrer FG, et al. N-palmitoyl-ethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag 2012; 2(2): 119-24.
[46]
Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat 2014; 2014854560
[47]
Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: Results from prospective and retrospective observational studies. Pain Ther 2015; 4(2): 169-78.
[48]
Chirchiglia D, Chirchiglia P, Signorelli F. Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): A series of 100 cases. Neurol Neurochir Pol 2018; 52(1): 44-7.
[49]
Paladini A, Varrassi G, Bentivegna G, Carletti S, Piroli A, Coaccioli S. Palmitoylethanolamide in the treatment of failed back surgery syndrome. Pain Res Treat 2017; 20171486010
